Multilineage Stem Cell Activity and High CRU Levels Are Maintained in AFT024 Cultures
Cells . | Week . | Lineage Contribution, % Ly5.2 Cells . | Total % Ly5.2 . | CRU/105 . | |||
---|---|---|---|---|---|---|---|
. | . | CD4 . | CD8 . | B220 . | Myeloid . | . | . |
With 1,000 purified fetal liver cells* | |||||||
Control | 5 | 3.3 ± 1.5 | 4.4 ± 1.7 | 48 ± 5.1 | 32 ± 6.0 | 28 ± 1.3 | 386 ± 24 |
12 | 27 ± 10 | 24 ± 8.7 | 63 ± 8.9 | 43 ± 9.2 | 44 ± 3.2 | 800 ± 102 | |
24 | 42 ± 6.9 | 34 ± 4.1 | 71 ± 4.4 | 62 ± 1.4 | 48 ± 4.8 | 984 ± 171 | |
AFT024 | 5 | 7.7 ± 6.2 | 6.0 ± 3.5 | 58 ± 6.6 | 36 ± 4.7 | 39 ± 2.1 | 641 ± 54 |
12 | 44 ± 7.1 | 38 ± 6.4 | 70 ± 5.6 | 53 ± 3.6 | 48 ± 1.4 | 942 ± 51 | |
24 | 56 ± 3.8 | 49 ± 3.1 | 72 ± 2.4 | 64 ± 3.7 | 56 ± 1.9 | 1,270 ± 96 | |
2012 | 5 | 0.8 ± 0.5 | 1.4 ± 0.3 | 6.8 ± 3.6 | 14 ± 11 | 7.4 ± 2.3 | 52 ± 8.5 |
12 | 9.1 ± 8.4 | 10 ± 6.9 | 14 ± 9.3 | 23 ± 20 | 14 ± 4.5 | 194 ± 68 | |
24 | 17 ± 3.8 | 18 ± 2.0 | 23 ± 5.9 | 32 ± 6.4 | 21 ± 4.4 | 196 ± 71 | |
Cells | Week | Lineage Contribution, % Ly5.2 Cells | CRU/105 | ||||
Myeloid | B Cells | T Cells | Total % | ||||
Ly 5.2 |
Cells . | Week . | Lineage Contribution, % Ly5.2 Cells . | Total % Ly5.2 . | CRU/105 . | |||
---|---|---|---|---|---|---|---|
. | . | CD4 . | CD8 . | B220 . | Myeloid . | . | . |
With 1,000 purified fetal liver cells* | |||||||
Control | 5 | 3.3 ± 1.5 | 4.4 ± 1.7 | 48 ± 5.1 | 32 ± 6.0 | 28 ± 1.3 | 386 ± 24 |
12 | 27 ± 10 | 24 ± 8.7 | 63 ± 8.9 | 43 ± 9.2 | 44 ± 3.2 | 800 ± 102 | |
24 | 42 ± 6.9 | 34 ± 4.1 | 71 ± 4.4 | 62 ± 1.4 | 48 ± 4.8 | 984 ± 171 | |
AFT024 | 5 | 7.7 ± 6.2 | 6.0 ± 3.5 | 58 ± 6.6 | 36 ± 4.7 | 39 ± 2.1 | 641 ± 54 |
12 | 44 ± 7.1 | 38 ± 6.4 | 70 ± 5.6 | 53 ± 3.6 | 48 ± 1.4 | 942 ± 51 | |
24 | 56 ± 3.8 | 49 ± 3.1 | 72 ± 2.4 | 64 ± 3.7 | 56 ± 1.9 | 1,270 ± 96 | |
2012 | 5 | 0.8 ± 0.5 | 1.4 ± 0.3 | 6.8 ± 3.6 | 14 ± 11 | 7.4 ± 2.3 | 52 ± 8.5 |
12 | 9.1 ± 8.4 | 10 ± 6.9 | 14 ± 9.3 | 23 ± 20 | 14 ± 4.5 | 194 ± 68 | |
24 | 17 ± 3.8 | 18 ± 2.0 | 23 ± 5.9 | 32 ± 6.4 | 21 ± 4.4 | 196 ± 71 | |
Cells | Week | Lineage Contribution, % Ly5.2 Cells | CRU/105 | ||||
Myeloid | B Cells | T Cells | Total % | ||||
Ly 5.2 |
With 100 purified fetal liver cells† | |||||||
AFT024 | 15 | 33 ± 4.6 | 41 ± 6.0 | 25 ± 5.3 | 28 ± 4.6 | 1,888 ± 315 | |
26 | 17 ± 4.4 | 18 ± 4.8 | 18 ± 5.9 | 24 ± 5.9 | 1,825 ± 571 | ||
46 | 22 ± 5.7 | 19 ± 6.6 | 15 ± 6.7 | 20 ± 6.5 | 1,595 ± 628 | ||
2012 | 15 | 32 ± 7.8 | 28 ± 7.2 | 20 ± 5.2 | 24 ± 6.6 | 1,390 ± 382 | |
26 | 10 ± 2.8 | 9.7 ± 3.2 | 9.7 ± 3.2 | 14 ± 3.9 | 699 ± 176 | ||
46 | 11 ± 2.3 | 6.7 ± 1.6 | 8.9 ± 3.2 | 9.0 ± 2.0 | 409 ± 80 | ||
Cells | Lineage Contribution, % Ly5.1 Cells | Total % | CRU/105 | ||||
CD4 | CD8 | B220 | Myeloid | Ly5.1 |
With 100 purified fetal liver cells† | |||||||
AFT024 | 15 | 33 ± 4.6 | 41 ± 6.0 | 25 ± 5.3 | 28 ± 4.6 | 1,888 ± 315 | |
26 | 17 ± 4.4 | 18 ± 4.8 | 18 ± 5.9 | 24 ± 5.9 | 1,825 ± 571 | ||
46 | 22 ± 5.7 | 19 ± 6.6 | 15 ± 6.7 | 20 ± 6.5 | 1,595 ± 628 | ||
2012 | 15 | 32 ± 7.8 | 28 ± 7.2 | 20 ± 5.2 | 24 ± 6.6 | 1,390 ± 382 | |
26 | 10 ± 2.8 | 9.7 ± 3.2 | 9.7 ± 3.2 | 14 ± 3.9 | 699 ± 176 | ||
46 | 11 ± 2.3 | 6.7 ± 1.6 | 8.9 ± 3.2 | 9.0 ± 2.0 | 409 ± 80 | ||
Cells | Lineage Contribution, % Ly5.1 Cells | Total % | CRU/105 | ||||
CD4 | CD8 | B220 | Myeloid | Ly5.1 |
With 100 purified BM cells‡ | |||||||
Control (n = 8) | 38 ± 7.3 | 30 ± 5.8 | 43 ± 6.7 | 31 ± 4.8 | 32 ± 6.5 | 583 ± 172 | |
AFT024 (n = 7) | 20 ± 9.8 | 18 ± 8.8 | 20 ± 8.7 | 24 ± 11 | 22 ± 10 | 490 ± 296 |
With 100 purified BM cells‡ | |||||||
Control (n = 8) | 38 ± 7.3 | 30 ± 5.8 | 43 ± 6.7 | 31 ± 4.8 | 32 ± 6.5 | 583 ± 172 | |
AFT024 (n = 7) | 20 ± 9.8 | 18 ± 8.8 | 20 ± 8.7 | 24 ± 11 | 22 ± 10 | 490 ± 296 |
AA4.1+ day 14 fetal liver cells (Ly5.2) were further purified for a lin−/lo, Sca-1+, c-kit+ stem cell surface phenotype. Fresh purified control cells (103) were transplanted with 106 Ly5.1 competitor marrow (n = 6 mice). From the same purification, 104 cells were cocultured with stromal cell lines for 4 weeks. Subsequently, 10% of each culture was transplanted per mouse (n = 8 mice/stroma) together with 106 competitor BM cells. The contribution to each lineage in peripheral blood is expressed as the percent of the total specific lineage population that was Ly5.2+. CRU/105, relative enrichment of competitive repopulating units. Data are the mean ± SEM.
The lineage and CRU content of low numbers of enriched fetal liver stem cells maintained on AFT024 and 2012 were determined. 500 stem cells were maintained in Dexter LTC for 4 to 7 weeks over irradiated monolayers. 20% of each culture was used to transplant groups of 4 mice (ie, each mouse received the equivalent of 100 stem cells that initially seeded the cultures) combined with 4 × 105 competitor BM cells. Data are the mean ± SEM.
Ly5.1 BM cells with a lin−/lo, Sca-1+, and c-kit+ cell surface phenotype were purified. 100 fresh cells per mouse (control) were transplanted with 105 Ly5.2 competitor BM cells. One thousand of the same purified cells were cocultured with stromal cell lines for 6 weeks. The cultures were then harvested, and 10% of each culture was transplanted per mouse with competitor. Data are from peripheral blood samples taken 4 months after transplant and are the mean ± SEM.